PE20050773A1 - Compuestos de quinolina sustituidos - Google Patents

Compuestos de quinolina sustituidos

Info

Publication number
PE20050773A1
PE20050773A1 PE2005000125A PE2005000125A PE20050773A1 PE 20050773 A1 PE20050773 A1 PE 20050773A1 PE 2005000125 A PE2005000125 A PE 2005000125A PE 2005000125 A PE2005000125 A PE 2005000125A PE 20050773 A1 PE20050773 A1 PE 20050773A1
Authority
PE
Peru
Prior art keywords
alkyl
quinoline
phenyl
integer number
biphenyl
Prior art date
Application number
PE2005000125A
Other languages
English (en)
Inventor
Peter Bertinato
Michel Andre Couturier
Marcus Douglas Ewing
Derek Lawrence Tickner
Ralph P Robinson
Ernest Seiichi Hamanaka
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of PE20050773A1 publication Critical patent/PE20050773A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)

Abstract

SE REFIERE A UN COMPUESTO DE QUINOLINA SUSTITUIDOS DE FORMULA (I) DONDE R1 ES UN GRUPO DE FORMULA R1a Y ESTA UNIDO A LA POSICION 2 o 3 DEL GRUPO QUINOLINA DE FORMULA I DONDE m ES UN NUMERO ENTERO DE 0 A 2, n ES UN NUMERO ENTERO DE 0 A 4, p ES UN NUMERO ENTERO DE 0 A 5, q ES UN NUMERO ENTERO DE 0 3, R ES UN ENLACE O UN NUMERO ENTERO DE 1 A 3; X ES -N O -C (Ra)- DONDE Ra ES H O R9 ; X1 ES -N- O -C (Rb )- DONDE Rb ES H O R7; R2 , R7 , R8 Y R9 SE SELECCIONAN DE HALO, -OH, -CN, ALQUILO (C1-C4), ALCOXI (C1-C4)-, R5 Y R10 SE SELECCIONAN CADA DE H, ALQUILO (C1-C4), ALQUILO (C1-C4) SUSTITUIDO CON HALO; R6 ES ALQUILO (C1-C10), PIRIDILO, FENILO O FENIL-ALQUILO (C1-C6)-, ALQUENILO (C2-C10); Y ES H, ALQUILO C1-C8, CICLOALQUILO C3-C7-ALQUILO C1-C6, ENTRE OTROS. SON COMPUESTOS PREFERIDOS (CARBAMOIL-FENIL-METIL)-AMIDA DEL ACIDO (S)-2-[(4'-TRIFLUOROMETIL-BIFENIL-2-CARBONIL)-AMINO]-QUINOLINA-6-CARBOXILICO, (METILCARBAMOIL-FENIL-METIL)-AMIDA DEL ACIDO (S)-2-[(4'-TRIFLUOROMETIL-BIFENIL-2-CARBONIL)-AMINO]-QUINOLINA-6-CARBOXILICO, [FENIL-(2,2,2-TRIFLUORO-ETILCARBAMOIL)METIL]-AMIDA DEL ACIDO 2-[(4'-TRIFLUOROMETIL-BIFENIL-2-CARBONIL)-AMINO]-QUINOLINA-6-CARBOXILICO, ENTRE OTROS. LOS COMPUESTOS DE QUINOLINA SON INHIBIDORES DE LA PROTEINA DE TRANSFERENCIA DE TRIGLICERIDOS MICROSOMAL (MTP) Y/O DE LA SECRECION DE LA APOLIPOPROTEINA B (APO B) UTILES EN EL CONTROL DEL PESO Y TRATAMIENTO DE LA OBESIDAD
PE2005000125A 2004-02-04 2005-02-02 Compuestos de quinolina sustituidos PE20050773A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54167804P 2004-02-04 2004-02-04
US63376304P 2004-12-06 2004-12-06

Publications (1)

Publication Number Publication Date
PE20050773A1 true PE20050773A1 (es) 2005-10-26

Family

ID=34890449

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2005000125A PE20050773A1 (es) 2004-02-04 2005-02-02 Compuestos de quinolina sustituidos

Country Status (25)

Country Link
US (3) US7468378B2 (es)
EP (1) EP1716137A1 (es)
JP (1) JP2007520543A (es)
KR (1) KR100799802B1 (es)
AP (1) AP2006003685A0 (es)
AR (1) AR047529A1 (es)
AU (1) AU2005214159A1 (es)
BR (1) BRPI0507462A (es)
CA (1) CA2555133A1 (es)
CO (1) CO5700721A2 (es)
CR (1) CR8544A (es)
EA (1) EA010369B1 (es)
EC (1) ECSP066717A (es)
GE (1) GEP20084360B (es)
IL (2) IL176715A0 (es)
MA (1) MA28347A1 (es)
NL (1) NL1028192C2 (es)
NO (1) NO20063928L (es)
OA (1) OA13365A (es)
PA (1) PA8623001A1 (es)
PE (1) PE20050773A1 (es)
SV (1) SV2007002007A (es)
TW (2) TWI306454B (es)
UY (1) UY28734A1 (es)
WO (1) WO2005080373A1 (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1682537T3 (pl) 2003-11-05 2012-09-28 Sarcode Bioscience Inc Modulatory adhezji komórkowej
AU2005214159A1 (en) * 2004-02-04 2005-09-01 Pfizer Products Inc. Substituted quinoline compounds
US7262318B2 (en) * 2004-03-10 2007-08-28 Pfizer, Inc. Substituted heteroaryl- and phenylsulfamoyl compounds
US20070203139A1 (en) * 2004-04-14 2007-08-30 Astrazeneca Ab Aryl Glycinamide Derivatives And Their Use As Nk1 Antagonists And Serotonin Reuptake Inhibitors
PA8660701A1 (es) 2005-02-04 2006-09-22 Pfizer Prod Inc Agonistas de pyy y sus usos
AU2006236226B2 (en) * 2005-04-19 2012-07-05 Surface Logix, Inc. Inhibitors of microsomal triglyceride transfer protein and Apo-B secretion
ES2368460T3 (es) * 2006-10-23 2011-11-17 Pfizer Inc. Compuestos de fenilmetil biciclocarboxiamida sustituidos.
KR20090064478A (ko) 2006-11-13 2009-06-18 화이자 프로덕츠 인크. 디아릴, 디피리디닐 및 아릴-피리디닐 유도체, 및 이들의 용도
WO2008097471A1 (en) * 2007-02-02 2008-08-14 Shivvers Steve D High efficiency drier with multi stage heating and drying zones
WO2008100423A1 (en) * 2007-02-09 2008-08-21 Sirtris Pharmaceuticals, Inc. Gut microsomal triglyceride transport protein inhibitors
WO2009014674A1 (en) * 2007-07-23 2009-01-29 Sirtris Pharmaceuticals, Inc. Heterocyclylamides as gut microsomal triglyceride transport protein inhibitors
ES2748136T3 (es) 2007-10-15 2020-03-13 United Animal Health Inc Método para aumentar el rendimiento de las crías
EP3797775A1 (en) * 2007-10-19 2021-03-31 Novartis AG Compositions and methods for treatment of diabetic retinopathy
WO2010018547A1 (en) * 2008-08-13 2010-02-18 Pfizer Inc. Aminoquinoline compounds
PE20140868A1 (es) 2011-06-24 2014-07-18 Amgen Inc Antagonistas trpm8 y su uso en tratamientos
WO2012177896A1 (en) 2011-06-24 2012-12-27 Amgen Inc. Trpm8 antagonists and their use in treatments
WO2013020062A1 (en) * 2011-08-04 2013-02-07 Array Biopharma Inc. Quinazoline compounds as serine/threonine kinase inhibitors
US8952009B2 (en) 2012-08-06 2015-02-10 Amgen Inc. Chroman derivatives as TRPM8 inhibitors
WO2015121877A2 (en) * 2014-02-17 2015-08-20 Hetero Research Foundation Polymorphs of lomitapide and its salts
KR102336926B1 (ko) 2014-10-06 2021-12-08 버텍스 파마슈티칼스 인코포레이티드 낭성 섬유증 막횡단 전도도 조절자의 조정제
US10138206B2 (en) 2014-10-09 2018-11-27 Glenmark Pharmaceuticals Limited Amorphous form of lomitapide mesylate
WO2017173274A1 (en) 2016-03-31 2017-10-05 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
PL3519401T3 (pl) 2016-09-30 2022-01-31 Vertex Pharmaceuticals Incorporated Modulator mukowiscydozowego przezbłonowego regulatora przewodnictwa, kompozycje farmaceutyczne, sposoby leczenia i proces wytwarzania modulatora
CN110267948B (zh) 2016-12-09 2023-12-08 弗特克斯药品有限公司 囊性纤维化跨膜传导调控剂的调节剂、药物组合物、治疗方法和制备所述调节剂的方法
WO2018227049A1 (en) 2017-06-08 2018-12-13 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
EP3640242B1 (en) * 2017-06-16 2023-04-19 Hitgen Ltd. Rock-inhibiting compound and uses thereof
US11517564B2 (en) 2017-07-17 2022-12-06 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
CA3071278A1 (en) 2017-08-02 2019-02-07 Vertex Pharmaceuticals Incorporated Processes for preparing pyrrolidine compounds
IL273831B1 (en) 2017-10-19 2024-06-01 Vertex Pharma Crystal forms and preparations of CFTR modulators
US11465985B2 (en) 2017-12-08 2022-10-11 Vertex Pharmaceuticals Incorporated Processes for making modulators of cystic fibrosis transmembrane conductance regulator
TWI810243B (zh) 2018-02-05 2023-08-01 美商維泰克斯製藥公司 用於治療囊腫纖化症之醫藥組合物
EP3774825A1 (en) 2018-04-13 2021-02-17 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2819039A1 (de) 1978-04-29 1979-11-08 Bayer Ag Leimungsmittel fuer papier
HU189569B (en) 1981-03-11 1986-07-28 The Wellcome Foudation Ltd,Gb Process for preparing 2-substituted phenyl/-benzoic acids and pharmaceutical compositons containing such compounds as active substances
ES2111065T5 (es) 1991-04-16 2005-06-16 Nippon Shinyaku Company, Limited Procedimiento para producir una dispersion solida.
HU218419B (hu) 1992-03-06 2000-08-28 E.R. Squibb And Sons, Inc. Mikroszomális triglicerid transzfer protein (MTP) nagy molekulatömegű alegységének rekombináns úton történő előállítására és a protein és inhibitorainak kimutatására szolgáló eljárások
US5595872A (en) 1992-03-06 1997-01-21 Bristol-Myers Squibb Company Nucleic acids encoding microsomal trigyceride transfer protein
US5739135A (en) 1993-09-03 1998-04-14 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
DK0804419T3 (da) 1994-05-27 2003-11-24 Glaxosmithkline Spa Quinolinderivater som tachykinin NK 3-receptor-antagonister
DE19504832A1 (de) 1995-02-14 1996-08-22 Basf Ag Feste Wirkstoff-Zubereitungen
DE19519245C2 (de) * 1995-04-14 2003-04-30 Boehringer Ingelheim Kg Neue Arylglycinamidderivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
EP0832069B1 (en) 1995-06-07 2003-03-05 Pfizer Inc. BIPHENYL-2-CARBOXYLIC ACID-TETRAHYDRO-ISOQUINOLIN-6-YL AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND/OR APOLIPOPROTEIN B (Apo B) SECRETION
DE69529849T2 (de) 1995-06-07 2003-09-04 Pfizer Biphenyl-2-carbonsäure-tetrahydro-isochinolin-6-yl amid derivate, deren hestellung und deren verwendung als inhibitoren des mikrosomalen triglycerid-transfer-proteins und/oder der apolipoprotein b (apo b) sekretion
US5827875A (en) 1996-05-10 1998-10-27 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
IL126557A (en) * 1996-05-20 2002-09-12 Darwin Discovery Ltd Quinoline (thio) carboxamides inhibiting TNF or PDE-IV and pharmaceutical preparations containing them
CA2259431A1 (en) 1996-07-01 1998-01-08 Eli Lilly And Company Hypoglycemic and hypolipidemic compounds
KR100217618B1 (ko) * 1996-12-12 1999-09-01 정몽규 와셔액 분사위치 조절 장치
AU5513298A (en) 1996-12-20 1998-07-17 Bristol-Myers Squibb Company Heterocyclic inhibitors of microsomal triglyceride transfer protein and method
US6066653A (en) 1997-01-17 2000-05-23 Bristol-Myers Squibb Co. Method of treating acid lipase deficiency diseases with an MTP inhibitor and cholesterol lowering drugs
US5968950A (en) 1997-06-23 1999-10-19 Pfizer Inc Apo B-secretion/MTP inhibitor hydrochloride salt
EP0901786B1 (en) 1997-08-11 2007-06-13 Pfizer Products Inc. Solid pharmaceutical dispersions with enhanced bioavailability
AP1201A (en) 1997-09-17 2003-09-01 Smithkline Beecham Corp Method for the synthesis of quinoline derivatives.
NZ505362A (en) * 1997-12-22 2004-12-24 Upjohn Co 4-hydroxyquinoline-3-carboxamides and -hydrazides useful as antiviral agents
CO5090829A1 (es) 1998-07-21 2001-10-30 Novartis Ag Compuestos organicos de la formula i, utiles como inhibido res de la proteina de transferencia de triglicerido microso mal y de la secrecion de la apolipoproteina b.
CO5271688A1 (es) 1999-11-10 2003-04-30 Pfizer Prod Inc Uso de inhibidor de secrecion de apoliproteinas b y/o de proteina de transferencia de trigliceridos microsmales
CA2325358C (en) 1999-11-10 2005-08-02 Pfizer Products Inc. 7-¬(4'-trifluoromethyl-biphenyl-2-carbonyl)amino|-quinoline-3-carboxylic acid amides, and methods of inhibiting the secretion of apolipoprotein b
US20020032238A1 (en) * 2000-07-08 2002-03-14 Henning Priepke Biphenylcarboxylic acid amides, the preparation thereof and the use thereof as medicaments
US6417367B1 (en) * 2000-08-11 2002-07-09 Pfizer Inc. Methods of making quinoline amides
EP1326835A1 (en) 2000-10-05 2003-07-16 Fujisawa Pharmaceutical Co., Ltd. Benzamide compounds as apo b secretion inhibitors
EE05452B1 (et) 2001-06-28 2011-08-15 Pfizer Products Inc. Triamiidasendatud indoolid, bensofuraanid ja bensotiofeenid kui mikrosomaalse trigltseriidide transportvalgu (MTP) ja/v?i apolipoproteiin B (apoB) sekretsiooni inhibiitorid
HUP0700124A2 (en) * 2001-10-25 2007-06-28 Takeda Chemical Industries Ltd Quinoline compound
WO2003049685A2 (en) * 2001-12-07 2003-06-19 The Regents Of The University Of California Treatment for age-related macular degeneration
US20030162788A1 (en) * 2002-01-10 2003-08-28 Boehringer Ingelheim Pharma Kg Combination of MTP inhibitors or apoB-secretion inhibitors with fibrates for use as pharmaceuticals
CN101838218A (zh) 2002-02-28 2010-09-22 日本烟草产业株式会社 酯化合物及其医药用途
CA2505604A1 (en) * 2002-12-20 2004-07-08 Pfizer Products Inc. Microsomal triglyceride transfer protein inhibitors
JP2006516028A (ja) * 2002-12-20 2006-06-15 ファイザー・プロダクツ・インク ミクロソームトリグリセリド輸送タンパク質阻害剤
AU2005214159A1 (en) * 2004-02-04 2005-09-01 Pfizer Products Inc. Substituted quinoline compounds

Also Published As

Publication number Publication date
WO2005080373A1 (en) 2005-09-01
EA010369B1 (ru) 2008-08-29
US7393958B2 (en) 2008-07-01
US7468378B2 (en) 2008-12-23
TW200906800A (en) 2009-02-16
UY28734A1 (es) 2005-09-30
TW200533354A (en) 2005-10-16
KR100799802B1 (ko) 2008-01-31
MA28347A1 (fr) 2006-12-01
GEP20084360B (en) 2008-04-29
IL176715A0 (en) 2006-10-31
AP2006003685A0 (en) 2006-08-31
JP2007520543A (ja) 2007-07-26
NL1028192C2 (nl) 2006-05-30
US20060223851A1 (en) 2006-10-05
US20070093525A1 (en) 2007-04-26
ECSP066717A (es) 2006-10-31
EA200601239A1 (ru) 2007-02-27
SV2007002007A (es) 2007-03-20
AU2005214159A1 (en) 2005-09-01
PA8623001A1 (es) 2006-03-24
OA13365A (en) 2007-04-13
CO5700721A2 (es) 2006-11-30
AR047529A1 (es) 2006-01-25
CA2555133A1 (en) 2005-09-01
KR20060127123A (ko) 2006-12-11
NL1028192A1 (nl) 2005-08-08
US7368573B2 (en) 2008-05-06
CR8544A (es) 2006-11-30
IL208963A0 (en) 2011-07-31
EP1716137A1 (en) 2006-11-02
TWI306454B (en) 2009-02-21
US20050234099A1 (en) 2005-10-20
NO20063928L (no) 2006-10-31
BRPI0507462A (pt) 2007-07-10

Similar Documents

Publication Publication Date Title
PE20050773A1 (es) Compuestos de quinolina sustituidos
PE20030135A1 (es) Derivados indol sustituido con triamida como inhibidores de la secrecion de mtp
PE20120655A1 (es) Derivados de triazolopiridina como inhibidores de proteinas cinasas activadas por mitogeno p38 (map)
PE20120334A1 (es) COMPUESTOS HETEROCICLICOS INHIBIDORES DE LAS PROTEINAS ANTI-APOPTOTICAS Bcl2
PE20081475A1 (es) Arilamidas sustituidas por tiazol u oxazol
PE20060727A1 (es) Antranilamidopiridinas como inhibidores de la quinasa receptora del factor de crecimiento vascular endotelial (vegf)
EA200870358A1 (ru) 2-(циклический амино) пиримидоновые производные в качестве ингибиторов tpk1
CO6160323A2 (es) Derivados de quinazolinona 5-sustituidos como agentes antitumorales
AR052156A1 (es) Fenil-metanonas bi- y triciclicas sustituidas para el tratamiento de trastornos neurologicos y neuropsiquiatricos
PE20141375A1 (es) Activadores de glucoquinasa
AR053340A1 (es) Derivados de trifluormetilbenzamida y sus usos terapeuticos
CO6160235A2 (es) Isoxazolinas insecticidas
PE20070078A1 (es) Compuestos heterociclicos macrociclicos como inhibidores de aspartil proteasa
PE20061150A1 (es) Derivados de n-(n-sulfonilaminoarilmetil)ciclopropanocarboxamida sustituidos como antagonistas del receptor vainilloide tipo 1 (vdr1)
PE20110398A1 (es) BENZAMIDAS CON ACTIVIDAD SOBRE LA ENZIMA p38 MAP-QUINASA
AR064355A1 (es) Herbicidas derivados de isoxazol
PE20090641A1 (es) Amidas heterociclicas
PE20080688A1 (es) Derivados de n-(amino-heteroaril)-1h-indol-2-carboxamidas como antagonistas de trpv1 y su preparacion
AR048042A1 (es) Inhibidores no nucleosidos de transcriptasa inversa y composiciones farmaceuticas
PE20080253A1 (es) Antagonistas de los receptores cgrp monociclicos sustituidos
PE20070069A1 (es) Piperazin-piperidinas como antagonistas y agonistas del receptor 5-ht1a
PE20020220A1 (es) Compuestos de nitrilo de dipeptido como inhibidores de catepsina k
PE20081549A1 (es) Derivados de n-(amino-heteroaril)-1h-pirrolopiridin-2-carboxamida y su preparacion
PE20120024A1 (es) DERIVADOS DE LA PIRIDINA SUSTITUIDO CON ANILLO HETEROCICLICO Y GRUPO y- GLUTAMINICO, Y AGENTES ANTIFUNGALES QUE LOS CONTIENEN
ES2531396T3 (es) Proceso para preparar compuestos de piridinona

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed